Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
Five-year data from the SOLO-1 Phase III trial is the longest follow-up analysis for any PARP inhibitor in the 1st-line maintenance settingAstraZeneca and MSD’s Lynparza (olaparib) demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response following platinum-based chemotherapy. Ovarian cancer is the eighth most common cause of cancer death in women worldwide and in 2018, there were nearly 300,000 new patients